OneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows
Onesource Specialty Pharma set out an expansion in a quarterly results development for FY28.
· LiveMint Markets
OneSource Specialty Pharma shares rose nearly 14% after the company reported Q2 revenue growth of 37% year-on-year and adjusted profit after tax of ₹93.7 crore. The company maintained its FY28 targets and expects expanded drug-device combination capacity to support future growth.
Key facts
- Period
- FY28
The analysis
Onesource Specialty Pharma reported ₹93.7 crore for FY28, with movement of 14%, 50% and 37% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +13.8% on the day at ₹1,589.80, and has returned -5.9% over three months. It sits 15% below its 52-week high. The pharma & healthcare sector has moved -2.3% over the same period, so Onesource Specialty Pharma is running 3.6 points behind its peers.
For Onesource Specialty Pharma, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Onesource Specialty Pharma (ONESOURCE), in Pharma & Healthcare.
- Over three months: Onesource Specialty Pharma -5.9% against Pharma & Healthcare -2.3% (3.6 points behind).
- Trading well above normal today: Onesource Specialty Pharma at 13.1 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Onesource Specialty PharmaONESOURCE · Pharma & Healthcare | ₹1,589.80 | +13.8% | -0.8% | -5.9% | -15.3% | 13.1× | — |
Pharma & Healthcare
1M -5.8% · 3M -2.3%
Onesource Specialty Pharma
Prices as of 27 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
Acutaas Chemicals rallies 13%; hits record high on strong Q2 results
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
Q2 Results Live: L&T, Maruti Suzuki, Tata Steel, Cipla, SBI Life, Bajaj Auto, Indus Towers, Waaree Energies In Focus